Profit Per Employee: $610,931
Biopharmacuetical company Gilead Sciences (NASDAQ:GILD) is focused in treatments for HIV/AIDS, liver diseases such as hepatitis B and C, and cardiovascular/metabolic and respiratory conditions.
With revenues of more than $2 billion, the 25-year old company is well-positioned in the biopharma world.
Premium pricings on its treatments help push Gilead forward on profit per employee, and its margins keep expanding.
Marc Bastow is an Assistant Editor at InvestorPlace.com. As of this writing, he did not hold a position in any of the aforementioned securities.